Ziconotide

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 13 September 2026

Ziconotide (Prialt) is a real, FDA-approved synthetic peptide derived from cone-snail venom — a non-opioid painkiller for severe chronic pain, delivered only by continuous infusion directly into spinal fluid.

In brief

Should you care? Only relevant for severe, treatment-refractory chronic pain managed through a surgically implanted intrathecal pump — not a peptide anyone self-administers.

The short version

An exact synthetic copy of a cone-snail venom peptide (ω-conotoxin MVIIA), blocking pain signals by a mechanism entirely unrelated to opioids.
Approved December 2004 on the strength of three placebo-controlled trials.
Carries a boxed warning for psychiatric and cognitive effects — a genuinely useful drug with a genuinely real risk, not a wellness product.

A cone-snail venom peptide, not an opioid

Ziconotide is a synthetic 25-amino-acid peptide, an exact copy of ω-conotoxin MVIIA, a component of the venom the fish-hunting cone snail Conus magus uses to paralyze prey. It blocks N-type voltage-gated calcium channels in the spinal cord's dorsal horn, interrupting pain-signal transmission before it reaches the brain. That mechanism has nothing to do with opioid receptors: no opioid activity, no tolerance buildup with continued use, and none of the respiratory-depression or addiction risk opioids carry. It also can't be given as a pill or ordinary injection — it doesn't cross the blood-brain barrier, so it has to be delivered continuously into the cerebrospinal fluid itself, almost always via a surgically implanted pump.

The approval and three pivotal trials

The FDA approved ziconotide (as Prialt) on 28 December 2004 for severe chronic pain in patients intolerant of, or refractory to, other treatments including intrathecal morphine. Three placebo-controlled randomized trials supported it, at three different levels of severity and titration speed. Staats et al. (JAMA 2004, PMID 14709577), 111 patients with cancer- or AIDS-related pain, found a 53.1% mean reduction in pain-intensity score with ziconotide over 5-6 days of rapid titration, versus 18.1% with placebo. Wallace et al. (Neuromodulation 2006;9(2):75-86, DOI 10.1111/j.1525-1403.2006.00055.x), 255 patients with chronic nonmalignant pain, found a 31.2% reduction versus 6.0% with placebo over a 6-day inpatient titration. Rauck et al. (J Pain Symptom Manage 2006;31(5):393-406), 220 patients with severe chronic pain, found a more modest but still statistically significant 14.7% improvement versus 7.2% with placebo — using a slower, 3-week outpatient-style titration adopted specifically to reduce the higher adverse-event rate seen in the faster-titration trials.

Safety

Ziconotide carries a boxed warning: it is contraindicated in patients with a preexisting history of psychosis, and severe psychiatric symptoms or cognitive impairment can occur during treatment, requiring frequent monitoring. Reported cognitive adverse reactions in trials include confusion (33%), memory impairment (22%), speech disorder (14%), and aphasia (12%) — the label directs discontinuation if serious neuropsychiatric signs appear. These effects are generally reversible after stopping the infusion, which is one reason it's restricted to specialist, closely monitored pain-clinic settings rather than any form of outpatient self-use.

Current status

Still marketed as Prialt, with no generic version. Ownership changed hands in March 2026, when TerSera Therapeutics closed the sale of its infusion-specialty business — including Prialt — to ESTEVE. It remains a niche, specialist-clinic drug for severe intractable chronic pain managed with implanted intrathecal pumps — the surgical delivery requirement alone rules out any wellness or grey-market presence.

References

Staats PS, Yearwood T, Charapata SG, et al., "Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS: A Randomized Controlled Trial," JAMA 2004;291(1):63-70, PMID 14709577.
Wallace MS, Charapata SG, Fisher R, et al., "Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial," Neuromodulation 2006;9(2):75-86, DOI: 10.1111/j.1525-1403.2006.00055.x.
Rauck RL, Wallace MS, Leong MS, et al., "A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain," J Pain Symptom Manage 2006;31(5):393-406.
FDA approval history for Prialt (ziconotide), 28 December 2004; TerSera Therapeutics, closing of divestiture of its Infusion Specialty Therapies business unit (including Prialt) to ESTEVE, 10 March 2026.